Literature DB >> 23973311

Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway.

Kouji Fukuyama1, Shunske Tanahashi, Masamitsu Hoshikawa, Rika Shinagawa, Motohiro Okada.   

Abstract

To clarify the anti-parkinsonian mechanisms of action of zonisamide (ZNS), we determined the effects of ZNS on tripartite synaptic transmission associated with kynurenine (KYN) pathway (KP) in cultured astrocytes, and transmission in both direct and indirect pathways of basal ganglia using microdialysis. Interactions between cytokines [interferon-γ (IFNγ) and tumor-necrosis factor-α (TNFα)] and ZNS on astroglial releases of KP metabolites, KYN, kynurenic-acid (KYNA), xanthurenic-acid (XTRA), cinnabarinic-acid (CNBA) and quinolinic-acid (QUNA), were determined by extreme liquid-chromatography with mass-spectrometry. Interaction among metabotropic glutamate-receptor (mGluR), KP metabolites and ZNS on striato-nigral, striato-pallidal GABAergic and subthalamo-nigral glutamatergic transmission was examined by microdialysis with extreme liquid-chromatography fluorescence resonance-energy transfer detection. Acute and chronic ZNS administration increased astroglial release of KYN, KYNA, XTRA and CNBA, but not QUNA. Chronic IFNγ administration increased the release of KYN, KYNA, CNBA and QUNA, but had minimal inhibitory effect on XTRA release. Chronic TNFα administration increased CNBA and QUNA, but not KYN, KYNA or XTRA. ZNS inhibited IFNγ-induced elevation of KYN, KYNA and QUNA, but enhanced IFNγ-induced that of CNBA. TNFα-induced rises in CNBA and QUNA were inhibited by ZNS. ZNS inhibited striato-nigral GABAergic, striato-pallidal GABAergic and subthalamo-nigral glutamatergic transmission via activation of groups II and III mGluRs. ZNS enhanced astroglial release of endogenous agonists of group II mGluR, XTRA and group III mGluR, CNBA. Activated endogenous mGluR agonists inhibited transmission in direct and indirect pathways of basal ganglia. These mechanisms contribute to effectiveness and well tolerability of ZNS as an adjunct treatment for Parkinson's disease during l-DOPA monotherapy. This article is part of the Special Issue entitled 'The Synaptic Basis of Neurodegenerative Disorders'.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Astrocyte; Cinnabarinic acid; Kynurenine pathway; Parkinson's disease; Xanthurenic acid; Zonisamide

Mesh:

Substances:

Year:  2013        PMID: 23973311     DOI: 10.1016/j.neuropharm.2013.08.002

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  17 in total

1.  Xanthurenic Acid Formation from 3-Hydroxykynurenine in the Mammalian Brain: Neurochemical Characterization and Physiological Effects.

Authors:  K V Sathyasaikumar; M Tararina; H-Q Wu; S A Neale; F Weisz; T E Salt; R Schwarcz
Journal:  Neuroscience       Date:  2017-10-12       Impact factor: 3.590

2.  Effects of levetiracetam on astroglial release of kynurenine-pathway metabolites.

Authors:  Kouji Fukuyama; Motohiro Okada
Journal:  Br J Pharmacol       Date:  2018-10-06       Impact factor: 8.739

3.  Interaction between Mesocortical and Mesothalamic Catecholaminergic Transmissions Associated with NMDA Receptor in the Locus Coeruleus.

Authors:  Motohiro Okada; Kouji Fukuyama
Journal:  Biomolecules       Date:  2020-07-01

4.  Amantadine Combines Astroglial System Xc- Activation with Glutamate/NMDA Receptor Inhibition.

Authors:  Tomosuke Nakano; Toshiki Hasegawa; Dai Suzuki; Eishi Motomura; Motohiro Okada
Journal:  Biomolecules       Date:  2019-05-17

5.  Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc<sup/>.

Authors:  Motohiro Okada; Kouji Fukuyama; Yasuhiro Kawano; Takashi Shiroyama; Yuto Ueda
Journal:  Pharmacol Res Perspect       Date:  2019-01-07

6.  Clozapine Normalizes a Glutamatergic Transmission Abnormality Induced by an Impaired NMDA Receptor in the Thalamocortical Pathway via the Activation of a Group III Metabotropic Glutamate Receptor.

Authors:  Kouji Fukuyama; Ryo Kato; Masahiko Murata; Takashi Shiroyama; Motohiro Okada
Journal:  Biomolecules       Date:  2019-06-17

7.  Activation of Astroglial Connexin is Involved in Concentration-Dependent Double-Edged Sword Clinical Action of Clozapine.

Authors:  Kouji Fukuyama; Ruri Okubo; Masahiko Murata; Takashi Shiroyama; Motohiro Okada
Journal:  Cells       Date:  2020-02-11       Impact factor: 6.600

8.  Pathogenesis and pathophysiology of autosomal dominant sleep-related hypermotor epilepsy with S284L-mutant α4 subunit of nicotinic ACh receptor.

Authors:  Kouji Fukuyama; Masashi Fukuzawa; Takashi Shiroyama; Motohiro Okada
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

9.  Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43.

Authors:  Kouji Fukuyama; Motohiro Okada
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

10.  Pharmacological Discrimination of Effects of MK801 on Thalamocortical, Mesothalamic, and Mesocortical Transmissions.

Authors:  Motohiro Okada; Kouji Fukuyama; Tomosuke Nakano; Yuto Ueda
Journal:  Biomolecules       Date:  2019-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.